Prognostic impact of initial maximum standardized uptake value of ¹⁸F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib

References

• PaesmansMSculierJPLibertPPrognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patientsJ Clin Oncol199513122112307738625
   PubMed Web of Science ®Google Scholar
• JiangAGChenHLLuHYThe relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancerBMC Cancer20151538625956656
   PubMed Web of Science ®Google Scholar
• SimmonsCPKoinisFFallonMTPrognosis in advanced lung cancer – a prospective study examining key clinicopathological factorsLung Cancer20158830430925870155
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKNorth-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med20103622380238820573926
   PubMed Web of Science ®Google Scholar
• EngleJAKolesarJMAfatinib: a first-line treatment for selected patients with metastatic non-small-cell lung cancerAm J Health Syst Pharm2014711933193825349236
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med20043502129213915118073
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCSpanish Lung Cancer GroupScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med200936195896719692684
   PubMed Web of Science ®Google Scholar
• PircherAUlspergerEHackRBasic clinical parameters predict gefitinib efficacy in non-small cell lung cancerAnticancer Res2011312949295521868543
   PubMed Web of Science ®Google Scholar
• MillerVAKrisMGShahNBronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancerJ Clin Oncol2004221103110915020612
   PubMed Web of Science ®Google Scholar
• SasakiRKomakiRMacapinlacH[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancerJ Clin Oncol2005231136114315718309
   PubMed Web of Science ®Google Scholar
• HoangJKHoaglandLFColemanRECoanADHerndonJEPatzEFJrPrognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinomaJ Clin Oncol2008261459146418349396
   PubMed Web of Science ®Google Scholar
• D’AddarioGPintilieMLeighlNBFeldRCernyTShepherdFAPlatinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literatureJ Clin Oncol2005232926293615728229
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol20111273574221783417
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol2013313327333423816960
   PubMed Web of Science ®Google Scholar
• WuYLZhouCLiamCKFirst-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE studyAnn Oncol2015261883188926105600
   PubMed Web of Science ®Google Scholar
• KawaguchiTAndoMAsamiKRandomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)J Clin Oncol2014321902190824841974
   PubMed Web of Science ®Google Scholar
• LeeJKShinJYKimSPrimary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory studyAnn Oncol2013242080208723559152
   PubMed Web of Science ®Google Scholar
• CoudertBCiuleanuTParkKSATURN Investigators. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapyAnn Oncol20122338839421610154
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet20053661527153716257339
   PubMed Web of Science ®Google Scholar
• ShepherdFADanceyJRamlauRProspective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyJ Clin Oncol2000182095210310811675
   PubMed Web of Science ®Google Scholar
• CiuleanuTStelmakhLCicenasSEfficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 studyLancet Oncol20121330030822277837
   PubMed Web of Science ®Google Scholar
• KarampeazisAVoutsinaASouglakosJPemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 studyCancer20131192754276423661337
   PubMed Web of Science ®Google Scholar
• GarassinoMCMartelliOBrogginiMErlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialLancet Oncol20131498198823883922
   PubMed Web of Science ®Google Scholar
• SchefflerMZanderTNogovaLPrognostic impact of [18F] fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinibPLoS One20138e5308123308140
   PubMed Web of Science ®Google Scholar
• NaIIParkJYKimKMSignificance of smoking history and FDG uptake for pathological N2 staging in clinical N2-negative non-small-cell lung cancerAnn Oncol2011222068207221257671
   PubMed Web of Science ®Google Scholar